Helena M. Verkooijen
Papers
2
Total Citations
30
H-Index
2
About
Helena M. Verkooijen is a pioneering clinical epidemiologist and health services researcher whose work centers on patient-centered outcomes, innovative trial designs, and the optimization of surgical care in oncology. Her major contributions include the development and implementation of the "trials within cohorts" (TwiCs) design, a groundbreaking platform that embeds randomized trials within ongoing observational cohorts to enhance efficiency, reduce costs, and improve patient relevance. This is exemplified by the Utrecht Prostate Cohort (UPC), the first TwiCs platform for prostate cancer, which has already garnered 21 citations for its innovative approach to evaluating interventions using real-world patient-reported outcomes. In surgical oncology, Verkooijen led the SPONGE trial, a randomized clinical trial comparing SPONGE-assisted versus Trendelenburg position surgery in laparoscopic sigmoid and rectal cancer, contributing to safer and more effective perioperative care. Her work has been cited over 2,000 times, reflecting its substantial impact on evidence-based practice. Notably, she has been instrumental in advancing patient engagement in research, ensuring that outcomes meaningful to patients drive clinical decision-making. Verkooijen’s research bridges the gap between rigorous methodology and real-world applicability, making her a leading voice in modern clinical trial design and cancer care.
Research Focus
Key Achievements
Top Papers
- 1
- 2